Tom Shrader

Tom Shrader is an accomplished Equity Research Analyst at BTIG since July 2018, focusing on complex therapeutics such as antibody-drug conjugates (ADCs), bispecific monoclonal antibodies (bi-mAbs), antisense oligonucleotides (ASOs), and peptide nucleic acids (PNAs), with a growing emphasis on neurodegeneration biomarkers like LRRK2, TREM2, and CD33, as well as gene therapy and non-oncology cell therapy. Previously, Tom served as an Equity Research Analyst at Stifel Financial Corp., investing in biotechnology growth companies, and held leadership roles at Yale University as Director of Strategic Corporate Partnerships, BMO Capital Markets as Managing Director, and Oscar Gruss & Son as an Equity Analyst. With extensive academic experience at Albert Einstein College of Medicine as both Associate and Assistant Professor, Tom holds a PhD in Molecular Biophysics and Biochemistry from Yale University, along with postdoctoral training at the Massachusetts Institute of Technology and a Bachelor's degree in Biophysics from The Johns Hopkins University.